(732) 390-7750
Contact Us
Payments
Make A Referral
Start typing & press "Enter" or "ESC" to close
Appointments
Locations
Providers
For Patients
Patient Care Information
Medical Oncology
Radiation Oncology
The Science of Treatment
Deep Inspiration Breath Hold (DIBH)
Leading-Edge HDR & LDR Brachytherapy
SpaceOAR Hydrogel
Intensity Modulated Radiation Therapy (IMRT)
Accelerated Partial Breast Irradiation (APBI)
Prone Breast Radiation Therapy
Prostate Seed Implantation
Proton Therapy
Skin Cancer Treatment
Stereotactic Body Radiation Therapy
Stereotactic Radiosurgery
TomoTherapy
Breast Care
Hematology
Theranostics
Osteoarthritis/Radiation
Palliative & Supportive Care
Social Work
Infusion
Pharmacy
Nutrition
Diagnoses
Patient Portals & Useful Links
CareSpace Patient Portal
Payment Portal
FAQ & Resources
Before Your First Visit
New Patients
Awards/Recognition
Upcoming Programs
Astera Past Programs
Magazine
Billing & Insurance
Financial Advocacy
FAQ
Online Resources
Dignicap
Research
Clinical Trials
About
Blogs
About Us
Our Physicians
Our Care Team
News & Events
Careers
EZH-302: A Phase 1b/3 Double-blind, Randomized, Active-controlled, 3-stage, Biomarker Adaptive Study of Tazemetostat or Placebo in Combination With Lenalidomide Plus Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
Condition: Follicular Lymphoma
Go To Trial Homepage